Study E7389-M044-504 is an observational, post-authorization, single-arm, prospective, multicenter cohort study conducted to characterize and determine the incidence of eribulin-induced peripheral neuropathy (PN), and the frequency and time to resolution of eribulin-induced PN in adult participants treated with eribulin in a real-life setting with locally advanced or metastatic breast cancer (MBC) who have progressed following at least one and up to three chemotherapeutic regimens for advanced disease.

Inclusion Criteria:

• Locally advanced or MBC with progression after at least one chemotherapeutic regimen for advanced disease eligible for treatment with eribulin according to Fachinformation. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting unless participants were not suitable for these treatments
• 1-3 prior chemotherapeutic regimens for advanced disease
• Age >=18 years at the time of Informed Consent
• Ability to understand and willingness to respond to questions related to their health
• Decision for the participant to start treatment with eribulin has been made prior to inclusion in this study.
• Signed written Informed Consent

Exclusion Criteria:

• Previous treatment with eribulin in any line of treatment
• Contraindication according to the Fachinformation of eribulin
• Pregnancy or lactation
• Participation in an interventional clinical trial at the same time

Female participants greater than or equal to (>=) 18 years with locally advanced or MBC